The partnership strengthens education, innovation, and patient access by combining global expertise with regional leadership in precision oncology.

February 27, 2026 – Wiesbaden, Germany and Miami, USA. The International Centers for Precision Oncology (QUANTALPHA) Foundation and the UroTeragLATAM Foundation have signed a Memorandum of Understanding during the WFNMB congress in Cartagena, Colombia to collaborate on advancing Theranostics education through the QUANTALPHA Academy for Theranostics, fostering research, and improving patient access to Theranostics in urological cancer across Latin America. The partnership aims to accelerate the adoption of precision oncology by combining QUANTALPHA ’s global expertise in Theranostics with UroTeragLATAM’s regional leadership in education and multidisciplinary collaboration in the field. Together, the foundations will promote innovation, enhance knowledge exchange, and support the advancements of Theranostics centers throughout the region.